Company intelligence / Profile preview

ParinGenix

Unknown, Unknown, United States

Ownership: Private
Development stage: Other

Overview

ParinGenix developed PGX-100, an intravenous 2-O, 3-O desulfated heparin, which reached Phase IIb clinical trials for acute COPD exacerbations; no definitive efficacy results or further progress have been reported since 2014

Therapeutic areas: Pulmonology
Modalities: Small moleculeSynthetic oligosaccharide
Industry: Biotech

Partnerships

Ligand Pharmaceuticals (exclusive license for patents covering desulfated heparins)

Beyond the preview

Go deeper on ParinGenix.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ParinGenix.

Explore the full profile